Incyte Corp
INCY102.690USD
+5.380+5.53%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
20.14BMarket Cap
17.03P/E TTM
More Details of Incyte Corp Company
Incyte Corporation is a biopharmaceutical company, which is focused on the discovery, development, and commercialization of therapeutics. The Company operates in two therapeutic areas. One therapeutic area is Hematology/Oncology, which is comprised of Myeloproliferative Neoplasms and Graft-Versus-Host Disease, as well as solid tumors and hematologic malignancies. Its other therapeutic area is Inflammation and Autoimmunity, which includes its Dermatology commercial franchise. Its hematology and oncology franchise are comprised of six products, which are JAKAFI (ruxolitinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), PEMAZYRE (pemigatinib), ICLUSIG (ponatinib), NIKTIMVO (axatilimab-csfr), and ZYNYZ (retifanlimab-dlwr), as well as numerous clinical development programs. The Company's pipeline also includes two first-in-class small molecule antagonist of Mas-related G protein-coupled receptor (MRGPRX2) and INCB000547, an oral MRGPRX4 antagonist.
Incyte Corp Info
Ticker SymbolINCY
Company nameIncyte Corp
IPO dateDec 06, 1993
CEOMeury (Bill)
Number of employees2617
Security typeOrdinary Share
Fiscal year-endDec 06
Address1801 Augustine Cut-Off
CityWILMINGTON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code19803
Phone13024986700
Websitehttps://www.incyte.com/
Ticker SymbolINCY
IPO dateDec 06, 1993
CEOMeury (Bill)
Company Executives of Incyte Corp
Name
Name/Position
Position
Shareholding
Change
Mr. Herve Hoppenot
Mr. Herve Hoppenot
Director
Director
1.43M
-0.20%
Mr. Julian C. Baker
Mr. Julian C. Baker
Independent Chairman of the Board
Independent Chairman of the Board
278.77K
--
Mr. Paul J. Clancy
Mr. Paul J. Clancy
Independent Director
Independent Director
147.17K
+0.19%
Mr. Jean-Jacques Bienaime ,
Mr. Jean-Jacques Bienaime ,
Independent Director
Independent Director
144.77K
+1.77%
Mr. Michael James Morrissey
Mr. Michael James Morrissey
Executive Vice President, Head - Global Technical Operations
Executive Vice President, Head - Global Technical Operations
85.84K
-0.38%
Dr. Katherine A. High, M.D.
Dr. Katherine A. High, M.D.
Independent Director
Independent Director
66.08K
+3.96%
Dr. Otis W. Brawley, M.D.
Dr. Otis W. Brawley, M.D.
Independent Director
Independent Director
50.10K
+5.29%
Dr. Susanne Schaffert, Ph.D.
Dr. Susanne Schaffert, Ph.D.
Independent Director
Independent Director
37.95K
+4.60%
Dr. Pablo J. Cagnoni
Dr. Pablo J. Cagnoni
President - Research and Development
President - Research and Development
35.48K
+62.39%
Mr. Lee Heeson
Mr. Lee Heeson
Executive Vice President - Incyte, International
Executive Vice President - Incyte, International
29.24K
-9.51%
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Herve Hoppenot
Mr. Herve Hoppenot
Director
Director
1.43M
-0.20%
Mr. Julian C. Baker
Mr. Julian C. Baker
Independent Chairman of the Board
Independent Chairman of the Board
278.77K
--
Mr. Paul J. Clancy
Mr. Paul J. Clancy
Independent Director
Independent Director
147.17K
+0.19%
Mr. Jean-Jacques Bienaime ,
Mr. Jean-Jacques Bienaime ,
Independent Director
Independent Director
144.77K
+1.77%
Mr. Michael James Morrissey
Mr. Michael James Morrissey
Executive Vice President, Head - Global Technical Operations
Executive Vice President, Head - Global Technical Operations
85.84K
-0.38%
Dr. Katherine A. High, M.D.
Dr. Katherine A. High, M.D.
Independent Director
Independent Director
66.08K
+3.96%
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
JAKAFI revenues
763.79M
62.84%
OPZELURA revenues
164.50M
13.53%
JAKAVI product royalty revenues
109.71M
9.03%
NIKTIMVO revenues
36.15M
2.97%
OLUMIANT product royalty revenues
33.48M
2.75%
Other
107.89M
8.88%
Relevant data have not been disclosed by the company yet.
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
JAKAFI revenues
763.79M
62.84%
OPZELURA revenues
164.50M
13.53%
JAKAVI product royalty revenues
109.71M
9.03%
NIKTIMVO revenues
36.15M
2.97%
OLUMIANT product royalty revenues
33.48M
2.75%
Other
107.89M
8.88%
Shareholding Stats
Updated: Tue, Nov 18
Updated: Tue, Nov 18
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Baker Bros. Advisors LP
15.66%
The Vanguard Group, Inc.
10.12%
Dodge & Cox
7.10%
BlackRock Institutional Trust Company, N.A.
5.87%
State Street Investment Management (US)
4.93%
Other
56.33%
Shareholders
Shareholders
Proportion
Baker Bros. Advisors LP
15.66%
The Vanguard Group, Inc.
10.12%
Dodge & Cox
7.10%
BlackRock Institutional Trust Company, N.A.
5.87%
State Street Investment Management (US)
4.93%
Other
56.33%
Shareholder Types
Shareholders
Proportion
Investment Advisor
38.71%
Investment Advisor/Hedge Fund
37.98%
Hedge Fund
20.00%
Pension Fund
4.42%
Research Firm
2.13%
Individual Investor
2.02%
Bank and Trust
1.14%
Sovereign Wealth Fund
0.85%
Family Office
0.34%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
1425
204.09M
103.95%
+86.81K
2025Q2
1423
201.60M
103.23%
-197.50K
2025Q1
1457
199.01M
102.81%
-12.15M
2024Q4
1448
191.80M
99.11%
-19.23M
2024Q3
1401
192.85M
100.02%
-35.92M
2024Q2
1385
209.06M
108.78%
-39.98M
2024Q1
1357
227.85M
101.54%
-21.15M
2023Q4
1323
228.89M
102.19%
-14.49M
2023Q3
1300
224.25M
100.13%
-17.63M
2023Q2
1306
220.30M
98.76%
-17.67M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Baker Bros. Advisors LP
30.74M
15.74%
+256.17K
+0.84%
Jun 30, 2025
The Vanguard Group, Inc.
20.05M
10.27%
+134.71K
+0.68%
Jun 30, 2025
Dodge & Cox
14.60M
7.47%
-269.15K
-1.81%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
11.69M
5.99%
-228.50K
-1.92%
Jun 30, 2025
State Street Investment Management (US)
9.88M
5.06%
-159.70K
-1.59%
Jun 30, 2025
AQR Capital Management, LLC
8.20M
4.2%
+1.47M
+21.75%
Jun 30, 2025
Renaissance Technologies LLC
3.88M
1.99%
+173.20K
+4.67%
Jun 30, 2025
Geode Capital Management, L.L.C.
4.35M
2.23%
+139.74K
+3.32%
Jun 30, 2025
LSV Asset Management
3.86M
1.98%
+223.86K
+6.15%
Jun 30, 2025
Arrowstreet Capital, Limited Partnership
2.73M
1.4%
+2.39M
+701.80%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Invesco Biotechnology & Genome ETF
5.42%
iShares Genomics Immunology and Healthcare ETF
5.11%
First Trust NYSE Arca Biotechnology Index Fund
3.75%
Bushido Capital US Equity ETF
2.47%
AAM Sawgrass US Large Cap Quality Growth ETF
2.44%
First Trust Health Care Alphadex Fund
2.4%
VanEck Biotech ETF
2.34%
Alger Russell Innovation ETF
2.18%
Virtus LifeSci Biotech Products ETF
2.16%
State Street SPDR S&P Biotech ETF
2.13%
View more
Invesco Biotechnology & Genome ETF
Proportion5.42%
iShares Genomics Immunology and Healthcare ETF
Proportion5.11%
First Trust NYSE Arca Biotechnology Index Fund
Proportion3.75%
Bushido Capital US Equity ETF
Proportion2.47%
AAM Sawgrass US Large Cap Quality Growth ETF
Proportion2.44%
First Trust Health Care Alphadex Fund
Proportion2.4%
VanEck Biotech ETF
Proportion2.34%
Alger Russell Innovation ETF
Proportion2.18%
Virtus LifeSci Biotech Products ETF
Proportion2.16%
State Street SPDR S&P Biotech ETF
Proportion2.13%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Incyte Corp?
The top five shareholders of Incyte Corp are:
Baker Bros. Advisors LP holds 30.74M shares, accounting for 15.74% of the total shares.
The Vanguard Group, Inc. holds 20.05M shares, accounting for 10.27% of the total shares.
Dodge & Cox holds 14.60M shares, accounting for 7.47% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 11.69M shares, accounting for 5.99% of the total shares.
State Street Investment Management (US) holds 9.88M shares, accounting for 5.06% of the total shares.
Baker Bros. Advisors LP holds 30.74M shares, accounting for 15.74% of the total shares.
The Vanguard Group, Inc. holds 20.05M shares, accounting for 10.27% of the total shares.
Dodge & Cox holds 14.60M shares, accounting for 7.47% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 11.69M shares, accounting for 5.99% of the total shares.
State Street Investment Management (US) holds 9.88M shares, accounting for 5.06% of the total shares.
What are the top three shareholder types of Incyte Corp?
The top three shareholder types of Incyte Corp are:
Baker Bros. Advisors LP
The Vanguard Group, Inc.
Dodge & Cox
Baker Bros. Advisors LP
The Vanguard Group, Inc.
Dodge & Cox
How many institutions hold shares of Incyte Corp (INCY)?
As of 2025Q3, 1425 institutions hold shares of Incyte Corp, with a combined market value of approximately 204.09M, accounting for 103.95% of the total shares. Compared to 2025Q2, institutional shareholding has increased by 0.73%.
What is the biggest source of revenue for Incyte Corp?
In FY2025Q2, the JAKAFI revenues business generated the highest revenue for Incyte Corp, amounting to 763.79M and accounting for 62.84% of total revenue.
